Company news
Shanghai MicuRx Pharmaceutical Co., Ltd. news in 2025
Shanghai MicuRx Pharmaceutical Co., Ltd.'s news releases, calls and decks from 2025, newest first.
Announcement on Transfer of Some of The Company's Wholly-owned Subsidiary Kerui Kaisi's Business To Four Wholly-owned Subsidiaries Including Kangyue Biology, etc.
November 17, 2025
Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025
November 7, 2025
Announcement on Voluntary Disclosure of the Issuance of Approval Notices for Supplementary Applications for Drugs and Supplementary Applications for Drug Clinical Trials
November 5, 2025
Announcement on Attending Three-Quarter Report Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction in 2025
November 4, 2025
Report for Q3 2025
October 27, 2025
Notice on the 3rd Extraordinary General Meeting in 2025
October 22, 2025
Announcement on Purchasing Liability Insurance for Directors and Senior Management Members
October 15, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
October 9, 2025
Announcement on Adding Extraordinary Proposal Supplementary Notice of the 2nd Extraordinary General Meeting in 2025
September 24, 2025
Announcement on Absence of Financial Assistance or Compensation Provided to the Investors in the Current Private Placement, Either Directly or Through Interested Parties
September 22, 2025
Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025
September 5, 2025
Report on the Transfer Result of Shareholders' Inquiry and Indicative Announcement on Change in Equity of Shareholder with Reaching 5% Shares Exceeding Integer Multiple of 5% and 1%
September 4, 2025
Announcement on Voluntary Disclosure of the Approval of Marketing Registration for Contezolid API from New Additional Manufacturer
September 1, 2025
Indicative Announcement on Pricing for Shareholder Inquiry Transfer
August 22, 2025
Shareholder's Inquiry Transfer Plan
August 21, 2025
Announcement on Resignation and Appointment of Deputy General Manager
August 19, 2025
Announcement on Continued Use of Idle Raised Funds Used for Cash Management
August 5, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
July 17, 2025
Announcement on Change of Sponsor Representative
July 15, 2025
Notice on Convening the 1st Extraordinary General Meeting in 2025
July 1, 2025
Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2024 Annual Report
June 27, 2025
Announcement on Resolution of the 2024 Annual General Meeting
June 5, 2025
Announcement on the Voluntary Disclosure of Acceptance of the New Drug Application for the Marketing Authorization of Contezolid Acefosamil Sodium for Injection
May 21, 2025
Announcement on Convening the Q1 2025 Performance Briefing
May 19, 2025
Announcement on the Resignation of Independent Directors
May 12, 2025
Report for Q1 2025
April 23, 2025
Announcement on Attending the 2024 SSE STAR Market Innovative Drug Industry Collective Performance Briefing
April 14, 2025
MicuRx: 15 Clinical and Preclinical Research Studies to be Presented at ESCMID Global 2025
April 8, 2025
Announcement on Vesting Results in the 1st Vesting Period of Initial Grant in 2023 Restricted Stock Incentive Plan and Shares Listing
March 20, 2025
Special Report on Deposit and Use of Raised Funds in 2024
March 17, 2025
MicuRx Pharmaceutical: Contezolid Global Phase III Clinical Trial Safety and Efficacy Evaluation Endorsed by Data Monitoring Committee, Promising Prospects for Diabetic Foot Infection Treatment
February 25, 2025
Announcement on Preliminary Earnings Estimate for 2024
February 14, 2025